Publications
DDW poster
|
2025
Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitis
ECCO presentation
|
2025
Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitis
DDW poster
|
2024
Novel orally delivered bispecific antibody for local GI activity: SOR102, an anti-TNFα/anti-IL-23 antibody in clinical development for treatment of Inflammatory Bowel Disease
UEG presentation
|
2024
First In Human Study Of SOR102, A Novel, Orally Delivered Bispecific Anti-TNF/Anti-IL-23 Domain Antibody In Clinical Development For The Treatment Of Inflammatory Bowel Disease
Nature
|
2021
Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease
Nature
|
2019
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients